| DESCRIPTION | - ADV DRUG DELIV REV., (201402), vol. 66, pages 110 - 116 | - |
| DESCRIPTION | - AKASHI, CURR. OPIN. GENET. DEV., (2001), vol. 11, no. 6, pages 660 - 666 | - |
| DESCRIPTION | - ALTSCHUL ET AL., NUCLEIC ACIDS RES., (1997), vol. 25, pages 3389 - 3402 | - |
| DESCRIPTION | - ARDIANI ET AL., CURR. GENE THER., (2012), vol. 12, no. 2, pages 77 - 91 | - |
| DESCRIPTION | - ASHKENAZI, NAT. REV. DRUG DISCOV., (2008), vol. 7, no. 12, pages 1001 - 12 | - |
| DESCRIPTION | - BAUER S ET AL., PROC NATLACADSCI USA, (2001), vol. 98, pages 9237 - 42 | - |
| DESCRIPTION | - BERGER ET AL., CLIN CANCER RES., (2008), vol. 14, no. 10, pages 3044 - 51 | - |
| DESCRIPTION | - BINDER ET AL., EMBO J., (1994), vol. 13, pages 1969 - 1980 | - |
| DESCRIPTION | - BOUR-JORDAN ET AL., IMMUNOL REV., (2011), vol. 241, no. 1, pages 180 - 205 | - |
| DESCRIPTION | - BRAHMER ET AL., J CLIN ONCOL., (2010), vol. 28, no. 19, pages 3167 - 75 | - |
| DESCRIPTION | - BRAHMER ET AL., N ENGL J MED., (2012), vol. 366, no. 26, pages 2455 - 65 | - |
| DESCRIPTION | - BRINCKER, CRIT. REV. ONCOL. HEMATOL., (1993), vol. 15, no. 2, pages 91 - 8 | - |
| DESCRIPTION | - BRUNELLE ET AL., METHODS ENZYMOL., (2013), vol. 530, pages 101 - 14 | - |
| DESCRIPTION | - CAPUT ET AL., PROC. NATL. ACAD. SCI. USA, (1986), vol. 83, pages 1670 - 1674 | - |
| DESCRIPTION | - CELIKOGLU ET AL., CANCER THERAPY, (2008), vol. 6, pages 545 - 552 | - |
| DESCRIPTION | - DUBENSKY TW JR; KANNE DB; LEONG ML, "Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants", THER ADV VACCINES, (201311), vol. 1, no. 4, pages 131 - 43 | - |
| DESCRIPTION | - ELMORE, TOXICOL PATHOL., (2007), vol. 35, no. 4, pages 495 - 516 | - |
| DESCRIPTION | - FOLKMAN, N. ENGL. J. MED., (1972), vol. 285, no. 21, pages 1182 - 6 | - |
| DESCRIPTION | - FRONT PHARMACOL., (20151201), vol. 6, page 286 | - |
| DESCRIPTION | - GEALL ET AL., SEMIN. IMMUNOL., (2013), vol. 25, no. 2, pages 152 - 159 | - |
| DESCRIPTION | - GRANER MW; LILLEHEI KO; KATSANIS E, "Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines", FRONT ONCOL., (20150106), vol. 4, page 379 | - |
| DESCRIPTION | - GRIFFITH ET AL., ANNU. REV. IMMUNOL., (2014), vol. 32, pages 659 - 702 | - |
| DESCRIPTION | - HANAHAN; FOLKMAN, CELL, (1996), vol. 86, no. 3, pages 353 - 64 | - |
| DESCRIPTION | - HEMMI H ET AL., NATURE, (2000), vol. 408, pages 740 - 5 | - |
| DESCRIPTION | - INT J NANOMEDICINE, (2014), vol. 9, pages 1833 - 1843 | - |
| DESCRIPTION | - KARLIN ET AL., PNAS USA, (1993), vol. 90, pages 5873 - 5877 | - |
| DESCRIPTION | - KORE ET AL., BIOORG. MED. CHEM., (2013), vol. 21, no. 15, pages 4570 - 4 | - |
| DESCRIPTION | - KROEMER, G. ET AL., "Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009", CELL DEATH & DIFFERENTIATION, (2009), vol. 16.1, pages 3 - 11 | - |
| DESCRIPTION | - LAI ET AL., DEVELOPMENT, (1995), vol. 121, pages 2349 - 2360 | - |
| DESCRIPTION | - MEYLAN, E.; J. TSCHOPP ET AL., NATURE, (2006), vol. 442, no. 7098, pages 39 - 44 | - |
| DESCRIPTION | - MEYLAN, E.; TSCHOPP, J., "Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses", MOL. CELL, (2006), vol. 22, pages 561 - 569 | - |
| DESCRIPTION | - MOOLTEN, CANCER RES., (1986), vol. 46, no. 10, pages 5276 - 81 | - |
| DESCRIPTION | - PERSANO ET AL., MOL. ASPECTS MED., (2007), vol. 28, no. 1, pages 87 - 114 | - |
| DESCRIPTION | - PRENDERGAST GC; SMITH C; THOMAS S; MANDIK-NAYAK L; LAURY-KLEINTOP L; METZ R; MULLER AJ, "Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer", CANCER IMMUNOL. IMMUNOTHER., vol. 63, no. 7, pages 721 - 35 | - |
| DESCRIPTION | - STEPINSKI ET AL., RNA, (2001), vol. 7, no. 10, pages 1486 - 95 | - |
| DESCRIPTION | - THAKUR R; MISHRA DP, "Pharmacological modulation of beta-catenin and its applications in cancer therapy", J CELL MOL MED., (201304), vol. 17, no. 4, pages 449 - 56 | - |
| DESCRIPTION | - WEBER, J., SEMIN. ONCOL., (2010), vol. 37, no. 5, pages 430 - 9 | - |
| DESCRIPTION | - WEINBERG ET AL., J. IMMUNOTHER., (2006), vol. 29, no. 6, pages 575 - 585 | - |
| DESCRIPTION | - WOO SR; CORRALES L; GAJEWSKI TF, "The STING pathway and the T cell-inflamed tumor microenvironment", TRENDS IMMUNOL., (20150307), vol. S1471-49, no. 15, pages 00019 - 8 | - |
| EXAMINATION | - C P CHIKKANNA-GOWDA ET AL, "Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12", GENE THERAPY, (20050801), vol. 12, no. 16, doi:10.1038/sj.gt.3302561, ISSN 0969-7128, pages 1253 - 1263, XP055014072 | |
| EXAMINATION | - I. MELERO ET AL, "Strict Requirement for Vector-Induced Type I Interferon in Efficacious Antitumor Responses to Virally Encoded IL12", CANCER RESEARCH, US, (20141219), vol. 75, no. 3, doi:10.1158/0008-5472.CAN-13-3356, ISSN 0008-5472, pages 497 - 507, XP055494161 | |
| OPPOSITION | - Anonymous, "IL12RB2 interleukin 12 receptor subunit beta 2 [ Homo sapiens (human) ]", Genbank AAL01442.1, (20200101), pages 1 - 2, Genbank AAL01442.1, URL: https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=3595, (20210115), XP055765709 | - |
| OPPOSITION | - COUGHLIN et al., "B7-1 and Interleukin 12 Synergistically Induce Effective Antitumor Immunity", Cancer Res., (19950000), vol. 55, pages 4980 - 4987, XP002035092 | - |
| OPPOSITION | - EMA, "Kymriah", Summary of Product Characteristics, pages 1 - 44, URL: https://www.ema.europa.eu/ | - |
| OPPOSITION | - EMA, "YESCARTA", Summary of Product Characteristics, pages 1 - 36, URL: https://www.ema.europa.eu/ | - |
| OPPOSITION | - FOWLER, "Conversation on CureVac's RNA-Based Therapeutics with CEO Ingmar Hoerr", Medgadget, (20140528), URL: https://www.medgadget.com/2014/05/ conversation-on-curevacs-rna-based-therapeutics-with-ceo-ingmar-hoerr.html | - |
| OPPOSITION | - HOERR INGMAR, "Stabilized messenger RNA (RNActive (TM)) as a tool for innovative gene delivery", TISSUE ENGINEERING, & 2ND INTERNATIONAL CONGRESS ON REGENERATIVE BIOLOGY/2ND INTERNATIONAL CONGRESS ON BIO-NANO-INTERFACE; STUTTGART, GERMANY; OCTOBER 09 -11, 2006, & 2ND INTERNATIONAL CONGRESS ON REGENERATIVE BIOLOGY/2ND INTERNATIONAL CONGRESS ON BIO-NANO-INTERFACE; STUTTGART, GERMANY; OCTOBER 09 -11, 2006, (20070401), vol. 13, no. 4, pages 886 - 887, XP009125215 | - |
| OPPOSITION | - José I Quetglas; Sara Labiano; Ángela Aznar M; Elixabet Bolaños; Arantza Azpilikueta; Inmaculada Rodriguez; Erkuden Casales; Alfonso R Sánchez-Paulete; Víctor Segura; Cristian Smerdou; Ignacio Melero, "Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL 12 Synergizes with PD- 1/PD-L1 Blockade", CANCER IMMUNOLOGY RESEARCH, (20150217), pages 449 - 454 | - |
| OPPOSITION | - MELO-CARDENAS et al., "Intratumoral delivery of CD 154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression", Cancer Gene Therapy, (20120000), vol. 19, pages 336 - 344 | - |
| OPPOSITION | - SMERDOU C, LILJESTROEM P, "Two-helper RNA system for production of recombinant Semliki Forest virus particles.", JOURNAL OF GENERAL VIROLOGY., SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD., GB, GB, (19990201), vol. 73, no. 2, ISSN 0022-1317, pages 1092 - 1098, XP002253873 | - |
| OPPOSITION | - MARTINON et al., "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome- entrapped mRNA", Eur. J. Immunol., (19930000), doi:10.1002/eji.1830230749, pages 1719 - 1722, XP002937540 | |
| OPPOSITION | - ZITVOGEL et al., "Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors", Eur. J. Immunol., (19960000), vol. 26, doi:10.1002/eji.1830260624, pages 1335 - 1341, XP000914702 | |
| OPPOSITION | - SCHEEL et al., "Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA", Eur. J. Immunol., (20050000), vol. 35, doi:10.1002/eji.200425656, pages 1557 - 1566, XP002462636 | |
| OPPOSITION | - Tomohide Tatsumi, Et Al, "B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma", Hepatology, No longer published by Elsevier, (19990801), vol. 30, no. 2, doi:10.1002/hep.510300219, ISSN 0270-9139, pages 422 - 429, XP055765665 | |
| OPPOSITION | - HEIDENREICH et al., "A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile", Int. J. Cancer, (20150000), vol. 137, doi:10.1002/ijc.29402, pages 372 - 384, XP055462897 | |
| OPPOSITION | - FOTIN-MLECZEK et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", J Gene Med., (20120000), vol. 14, no. 6, doi:10.1002/jgm.2605, pages 428 - 39, XP002719717 | |
| OPPOSITION | - FOTIN-MLECZEK et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", Journal of Gene Medicine, (20120000), vol. 14, no. 6, doi:10.1002/jgm.2605, pages 428 - 439, XP002719717 | |
| OPPOSITION | - FOTIN-MLECZEK et al., "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", The Journal of Gene Medicine,, (20120000), pages 428 - 439, XP002716014 | |
| OPPOSITION | - AMOS et al., "Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice", Cancer Immunology and Immunotherapy, (20110000), vol. 60, no. 5, doi:10.1007/s00262-011-0984-8, pages 671 - 683, XP055285721 | |
| OPPOSITION | - SINGH et al., "Intratumoral immunotherapy for melanoma", Cancer Immunology, Immunotherapy, (20150607), vol. 64, no. 7, pages 911 - 921, XP055718477 | |
| OPPOSITION | - SINGH et al., "An alphavirus-based therapeutic cancer vaccine: from design to clinical trial , Cancer Immunology", Immunotherapy, (20190000), vol. 68, doi:10.1007/s00262-018-2276-z, pages 849 - 859, XP036760456 | |
| OPPOSITION | - SATO et al., "Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy", Immunol Res., (20110000), vol. 51, no. 2-3, doi:10.1007/s12026-011-8262-6, pages 170 - 82, XP019990832 | |
| OPPOSITION | - BONTKES et al., "Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells", Clinical Immunology, (20080000), vol. 127, no. 3, doi:10.1016/j.clim.2008.02.001, pages 375 - 384, XP022673824 | |
| OPPOSITION | - YAMAMOTO et al., "Current prospects for mRNA gene delivery", Euro. J. Pharm. Biopharm., (20090000), vol. 71, doi:10.1016/j.ejpb.2008.09.016, pages 484 - 489, XP025992169 | |
| OPPOSITION | - PARDI et al., "Expression kinetics of nucleoside- modified mRNA delivered in lipid nanoparticles to mice by various routes /Manuscript/", Journal of Controlled Release, (20150804), pages 1 - 18, XP055718468 | |
| OPPOSITION | - AMMI et al., "Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs", Pharmacology and Therapeutics, (20140000), vol. 146, doi:10.1016/j.pharmthera.2014.09.010, pages 120 - 131, XP029132937 | |
| OPPOSITION | - Rodriguez-Madoz, J.R. Prieto, J. Smerdou, C., "Semliki Forest Virus Vectors Engineered to Express Higher IL-12 Levels Induce Efficient Elimination of Murine Colon Adenocarcinomas", Molecular Therapy, No longer published by Elsevier, (20050701), vol. 12, no. 1, doi:10.1016/j.ymthe.2005.02.011, ISSN 1525-0016, pages 153 - 163, XP004925165 | |
| OPPOSITION | - BARRATT, "Therapeutic applications of colloidal drug carriers", PSTT, (20000000), vol. 3, doi:10.1016/S1461-5347(00)00255-8, pages 163 - 171, XP055626062 | |
| OPPOSITION | - TUGUES et al., "New insights into IL -12-mediated tumor suppression", Cell Death and Differentiation, (20140000), vol. 22, no. 2, doi:10.1038/cdd.2014.134, pages 237 - 246, XP055285716 | |
| OPPOSITION | - TUGUES et al., "New insights into IL -12-mediated tumor suppression", Cell Death & Differentiation,, (20140905), pages 237 - 246, XP055285716 | |
| OPPOSITION | - CRONIN et al., "Bacterial vectors for imaging and cancer gene therapy: a review", Cancer Gene Therapy, (20120000), vol. 19, doi:10.1038/cgt.2012.59, pages 731 - 740, XP055267237 | |
| OPPOSITION | - STADLER et al., "Elimination of large tumors in mice by mRNA-encoded bispecific antibodies", Nature Medicine,, (20170612), XP055410619 | |
| OPPOSITION | - PARDOLL et al., "The blockade of immune checkpoints in cancer immunotherapy", Nature Reviews Cancer, (20120000), vol. 12, no. 4, doi:10.1038/nrc3239, pages 252 - 264, XP055415943 | |
| OPPOSITION | - SAHIN et al., "mRNA-based therapeutics - developing a new class of drugs", Nat. Rev. Drug Discovery, (20140000), vol. 13, doi:10.1038/nrd4278, pages 759 - 780, XP055544673 | |
| OPPOSITION | - Ugur Sahin et al, "mRNA-based therapeutics — developing a new class of drugs", Nature Reviews Drug Discovery, Nature Pub. Group, vol. 13, no. 10, doi:10.1038/nrd4278, ISSN 14741776, pages 759 - 780, XP055159205 | |
| OPPOSITION | - Takashi Saika, Et Al, "Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model", Cancer Gene Therapy, Appleton & Lange, GB, GB, (20040501), vol. 11, no. 5, doi:10.1038/sj.cgt.7700709, ISSN 0929-1903, pages 317 - 324, XP055765642 | |
| OPPOSITION | - MAHVI et al., "Intratumoral injection of IL -12 plasmid DNA - results of a phase I/IB clinical trial", Cancer Gene Ther., (20070000), vol. 14, no. 8, doi:10.1038/sj.cgt.7701064, pages 717 - 23, XP055492519 | |
| OPPOSITION | - MAHVI et al., "Intratumoral injection of IL -12 plasmid DNA - results of a phasel/IB clinical trial", Cancer Gene Therapy, (20070000), vol. 14, doi:10.1038/sj.cgt.7701064, pages 717 - 723, XP055492519 | |
| OPPOSITION | - CHONG et al., "Tumour cell expression of B7 costimulatory molecules and interleukin-12 or granulocyte-macrophage colony stimulating factor induces a local antitumour response and may generate systemic protective immunity", Gene Therapy, (19980000), vol. 5, doi:10.1038/sj.gt.3300584, pages 223 - 232, XP000909569 | |
| OPPOSITION | - SCHIRRMACHER et al., "Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine", Gene Therapy, (20000000), pages 1137 - 1147, XP002359468 | |
| OPPOSITION | - SCHIRRMACHER et al., "Intra-pinna anti-tumor vaccination with self- replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine", GENE THERAPY, (20000000), vol. 7, no. 13, doi:10.1038/sj.gt.3301220, pages 1137 - 1147, XP002359468 | |
| OPPOSITION | - CHIKKANA-GOWDA et al., "Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL -12", Gene Therapy, (20050000), vol. 12, doi:10.1038/sj.gt.3302561, pages 1253 - 1263, XP055014072 | |
| OPPOSITION | - CHIKKANNA-GOWDA et al., "Regression of mouse tumors and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL -12", Gene Therapy, (20050000), vol. 12, no. 16, doi:10.1038/sj.gt.3302561, pages 1253 - 1263, XP055014072 | |
| OPPOSITION | - WEBER et al., "Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer-Preclinical Background: CTLA-4 and PD-1 Blockade", SEMINARS IN ONCOLOGY, (20101000), vol. 37, no. 5, page 430, XP009177527 | |
| OPPOSITION | - WEBER, "Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer-Preclinical Background: CTLA-4 and PD-1 Blockade", Seminars in Oncology, (20100000), vol. 37, no. 5, doi:10.1053/j.seminoncol.2010.09.005, pages 430 - 439, XP009177527 | |
| OPPOSITION | - PUTZER BRIGITTE M ET AL, "Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression", Proceedings of the National Academy of Sciences, National Academy of Sciences, (19970101), vol. 94, no. 20, doi:10.1073/pnas.94.20.10889, ISSN 0027-8424, pages 10889 - 10894, XP002421569 | |
| OPPOSITION | - PÜTZER et al., "Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression", Proceedings of The National Academy of Sciences USA, (19970000), vol. 94, no. 20, doi:10.1073/pnas.94.20.10889, pages 10889 - 10894, XP002421569 | |
| OPPOSITION | - Kevin Van Der Jeught et al, "Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy", OncoImmunology, (20150504), vol. 4, no. 5, doi:10.1080/2162402X.2015.1005504, page e1005504, XP055463808 | |
| OPPOSITION | - Kevin Van Der Jeught; Sandra Van Lint; Kris Thielemans; Karine Breckpot, "Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy", OncoImmunology, (20150500), page e1005504, XP055463808 | |
| OPPOSITION | - Kevin Van Der Jeught, Sandra Van Lint, Kris Thielemans, Karine Breckpot, "Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy", OncoImmunology, (20150504), vol. 4, no. 5, doi:10.1080/2162402X.2015.1005504, page e1005504, XP055463808 | |
| OPPOSITION | - PIERCE et al., "In-situ tumor vaccination: Bringing the fiht to the tumor", HUMAN VACCINES AND IMMUNOTHERAPEUTICS, (20150811), pages 1901 - 1909, XP055718472 | |
| OPPOSITION | - Robert H Pierce et al, "In-situ tumor vaccination: Bringing the fight to the tumor", Human vaccines & immunotherapeutics, Taylor & Francis, US, US, (20150803), vol. 11, no. 8, doi:10.1080/21645515.2015.1049779, ISSN 2164-5515, pages 1901 - 1909, XP055718472 | |
| OPPOSITION | - Johannes Vom Berg et al, "Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection", The Journal of Experimental Medicine, Rockefeller University Press, US, US, (20131216), vol. 210, no. 13, doi:10.1084/jem.20130678, ISSN 0022-1007, pages 2803 - 2811, XP055513130 | |
| OPPOSITION | - Johannes Vom Berg; Melissa Vrohlings; Sergio Haller; Aladin Haimovici; Paulina Kulig; Anna Sledzinska; Michael Weller; Burkhard Becher, "Intratumoral IL -12 combined with CTLA-4 blockade elicits T cell -mediated glioma reiection Year", The Journal of Experimental, (20130000), pages 2803 - 2811, XP055513130 | |
| OPPOSITION | - VOM BERG et al., "Intratumoral IL -12 combined with CTLA-4 blockade elicits T cell -mediated glioma rejection", J Exp Med., (20130000), vol. 210, no. 13, doi:10.1084/jem.20130678, pages 2803 - 11, XP055513130 | |
| OPPOSITION | - VOM BERG et al., "Intratumoral IL -12 combined with CTLA-4 blockade elicits T cell -mediated glioma rejection", J Exp Med., (20130000), vol. 210, no. 13, doi:10.1084/jem.20130678, pages 2803 - 2811, XP055513130 | |
| OPPOSITION | - WILGENHOF et al., "A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients", Annals of Oncology, (20130000), vol. 24, no. 10, doi:10.1093/annonc/mdt245, pages 2686 - 2693, XP009174113 | |
| OPPOSITION | - PUTZER et al., "Large Nontransplanted Hepatocellular Carcinoma in Woodchucks: Treatment With Adenovirus-Mediated Delivery of Interleukin 12/B7.1 Genes", J. Natl. Cancer Institute, (20010000), vol. 93, doi:10.1093/jnci/93.6.472, pages 472 - 479, XP002421568 | |
| OPPOSITION | - Jennifer Couzin-Frankel, "Cancer Immunotherapy", Science, doi:10.1126/science.342.6165.1432, (20131219), pages 1432 - 1433, Science, URL: http://science.sciencemag.org/content/342/6165/1432.full.pdf, (20170531), XP055377323 | |
| OPPOSITION | - Chengyong Jiang, D. Mitchell Magee, Rebecca A. Cox, "Construction of a Single-Chain Interleukin-12-Expressing Retroviral Vector and Its Application in Cytokine Gene Therapy against Experimental Coccidioidomycosis", Infection and Immunity, American Society for Microbiology, UNITED STATES, UNITED STATES, (19990601), pages 2996 - 3001, Infection and Immunity, URL: http://iai.asm.org/content/67/6/2996.full.pdf#page=1&view=FitH, XP055351282 | |
| OPPOSITION | - K. Kallio, K. Hellstrom, G. Balistreri, P. Spuul, E. Jokitalo, T. Ahola, "Template RNA Length Determines the Size of Replication Complex Spherules for Semliki Forest Virus", Journal of Virology, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, US, (20130815), vol. 87, no. 16, doi:10.1128/JVI.00660-13, ISSN 0022-538X, pages 9125 - 9134, XP055765691 | |
| OPPOSITION | - MELERO et al., "Strict Requirement for Vector-Induced Type I Interferon in Efficacious Antitumor Responses to Virally Encoded IL 12", Cancer Res., (20150000), vol. 75, no. 3, doi:10.1158/0008-5472.CAN-13-3356, pages 497 - 507, XP055494161 | |
| OPPOSITION | - MELERO et al., "Strict Requirement for Vector-Induced Type I Interferon in Efficacious Antitumor Responses to Virally Encoded IL 12", Cancer Research, (20140000), vol. 75, no. 3, doi:10.1158/0008-5472.CAN-13-3356, pages 497 - 507, XP055494161 | |
| OPPOSITION | - TRIOZZI et al., "Phase I Study of the Intratumoral Administration of Recombinant Canarypox Viruses Expressing B7.1 and Interleukin 12 in Patients with Metastatic Melanoma", Clinical Cancer Research, (20050000), vol. 11, no. 11, pages 4168 - 4175, XP055046157 | |
| OPPOSITION | - José I. Quetglas et al, "Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade", CANCER IMMUNOLOGY RESEARCH, American Association for Cancer Research, US, US, (20150501), vol. 3, no. 5, doi:10.1158/2326-6066.CIR-14-0216, ISSN 2326-6066, pages 449 - 454, XP055576398 | |
| OPPOSITION | - QUETGLAS et al., "Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL 12 Synergizes with PD-1/PD-L1 Blockade", Cancer Immunology Research, (20150000), vol. 3, doi:10.1158/2326-6066.CIR-14-0216, pages 449 - 454, XP055576398 | |
| OPPOSITION | - QUETGLAS et al., "Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL 12 Synergizes with PD-1/PD-L1 Blockade", Cancer Immunol Res., (20150000), vol. 3, no. 5, doi:10.1158/2326-6066.CIR-14-0216, pages 449 - 54, XP055576398 | |
| OPPOSITION | - QUETGLAS et al., "Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL 12 Synergizes with PD-1/PD-L1 Blockade", Cancer Immunol Res., (20150217), vol. 3, no. 5, doi:10.1158/2326-6066.CIR-14-0216, pages 449 - 454, XP055576398 | |
| OPPOSITION | - VAN LINT et al., "Intratumoral Delivery of TriMix mRNA Results in T- cell Activation by Cross-Presenting Dendritic Cells", CANCER IMMUNOLOGY RESEARCH, (20151211), pages 146 - 156, XP055532637 | |
| OPPOSITION | - KALLEN et al., "A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs", Ther Adv Vaccines, (20140000), vol. 2, no. 1, doi:10.1177/2051013613508729, pages 10 - 31, XP055126338 | |
| OPPOSITION | - DAUD et al., "Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100)", Journal of Translational Medicine,, (20150115), no. Suppl1, page O11, XP021208151 | |
| OPPOSITION | - Elias J Sayour; et al, "Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics", Journal for ImmunoTherapy of Cancer, BioMed Central, London, GB, GB, (20150421), vol. 3, no. 1, doi:10.1186/s40425-015-0058-0, ISSN 2051-1426, page 13, XP021216038 | |
| OPPOSITION | - Pascolo S, "Vaccination with messenger RNA", METHODS IN MOLECULAR MEDICINE, Humana Press, (20060101), ISSN 1543-1894, pages 23 - 40, XP009117840 | |
| OPPOSITION | - VAN LINT et al., "The ReNAissanCe of mRNA-based cancer therapy", Expert Rev. Vaccines Early online, (20140000), pages 1 - 17, XP55765682 | |
| OPPOSITION | - Kevin Van Der Jeught, Et Al, "Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity", Oncotarget, (20141030), vol. 5, no. 20, doi:10.18632/oncotarget.2463, pages 10100 - 10113, XP055765698 | |
| OPPOSITION | - Kevin Van Der Jeught et al, "Targeting the tumor microenvironment to enhance antitumor immune responses", Oncotarget, Impact Journals LLC, United States, United States, doi:10.18632/oncotarget.3204, (20150130), pages 1359 - 1381, Oncotarget, URL: http://pubmedcentralcanada.ca/pmcc/articles/PMC4359300/pdf/oncotarget-06-1359.pdf, (20170306), XP055351674 | |
| OPPOSITION | - VAN DER JEUGHT et al., "Targeting the tumor microenvironment to enhance antitumor immune responses", Oncotarget, (20141226), pages 1359 - 1381, XP055351674 | |
| OPPOSITION | - FRENZEL et al., "Expression of recombinant antibodies", Frontiers in Immunology, (20130000), vol. 4, doi:10.3389/fimmu.2013.00217, XP055283974 | |
| OPPOSITION | - Kenneth Lundstrom, "Alphaviruses in Gene Therapy", Viruses, vol. 7, no. 5, doi:10.3390/v7052321, pages 2321 - 2333, XP055765684 | |
| OPPOSITION | - LIECHTENSTEIN et al., "Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid- derived suppressor cells as a readout of therapeutic efficacy", ONCOIMMUNOLOGY, (20140000), page e945378, XP055298184 | |
| OPPOSITION | - DALPKE et al., "RNA mediated toll-like receptor stimulation in health and disease rNA", Biology, vol. 9, no. 6, doi:10.4161/rna.20206, pages 828 - 842, XP055075460 | |
| OTHER | - "Interleukin 12", Wikipedia, (20190212), URL: https://en.wikipedia.org/wiki/Interleukin_12, XP055576395 | - |
| OTHER | - MAHVI et al., "Intratumoral injection of IL-12 plasmid DNA - results of a phaseI/IB clinical trial", Cancer Gene Therapy, (20070000), vol. 14, pages 717 - 723, XP055492519 | |
| OTHER | - VAN DER JEUGHT et al., "Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy", Oncolmmunology, (20150500), vol. 4, no. 5, pages e1005504-1 - e1005504-3, XP055463808 | |
| OTHER | - VOM BERG et al., "Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection", J. Exp Med., (20130000), vol. 210, no. 13, pages 2803 - 2811, XP055513130 | |
| OTHER | - QUETGLAS et al., "Virotherapy with a Semliki Forest Virus-Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade", Cancer Immunol Res., (20150217), vol. 3, no. 5, pages 449 - 454, XP055576398 | |
| OTHER | - VAN DER JEUGHT et al., "Targeting the tumor microenvironment to enhance antitumor immune responses", Oncotarget, (20140000), vol. 6, no. 3, pages 1359 - 1381, XP055351674 | |
| SEARCH | - FOTIN-MLECZEK M ET AL, "Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect", JOURNAL OF GENE MEDICINE, JOHN WILEY & SONS, INC, US, vol. 14, no. 6, doi:10.1002/JGM.2605, ISSN 1099-498X, (20120601), pages 428 - 439, (20120627), XP002716014 [X] 1-10 * abstract * * page 428, paragraph 1 - page 437, column r, paragraph 2 * [Y] 1-10,27-30 [I] 1-10,27-30 | |
| SEARCH | - SALLY M. AMOS ET AL, "Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, (20110501), vol. 60, no. 5, doi:10.1007/s00262-011-0984-8, ISSN 0340-7004, pages 671 - 683, XP055285721 [Y] 1-10 * abstract * * page 671, column r, paragraph 1 - page 681, column l, paragraph 3 * | |
| SEARCH | - BONTKES H J ET AL, "Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 127, no. 3, doi:10.1016/J.CLIM.2008.02.001, ISSN 1521-6616, (20080601), pages 375 - 384, (20080321), XP022673824 [X] 1-8 * abstract * * page 375, column l, paragraph 1 - page 383, column r, paragraph 2 * [Y] 1-10,27-30 [I] 1-10,27-30 | |
| SEARCH | - AMMI RACHID ET AL, "Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs", PHARMACOLOGY AND THERAPEUTICS, (20141014), vol. 146, doi:10.1016/J.PHARMTHERA.2014.09.010, ISSN 0163-7258, pages 120 - 131, XP029132937 [Y] 1-10,27-30 * abstract * * page 120, column l, paragraph 1 - page 129, column l, paragraph 4 * | |
| SEARCH | - S TUGUES ET AL, "New insights into IL-12-mediated tumor suppression", CELL DEATH AND DIFFERENTIATION., GB, (20140905), vol. 22, no. 2, doi:10.1038/cdd.2014.134, ISSN 1350-9047, pages 237 - 246, XP055285716 [I] 1-10,27-30 * abstract * * page 237, column l, paragraph 1 - page 243, column r, paragraph 1 * * table 1 * [Y] 1-10,27-30 | |
| SEARCH | - DREW M. PARDOLL, "The blockade of immune checkpoints in cancer immunotherapy", NATURE REVIEWS CANCER, (20120322), vol. 12, no. 4, doi:10.1038/nrc3239, ISSN 1474-175X, pages 252 - 264, XP055150744 [I] 1-6,27-30 * abstract * * page 252, column l, paragraph 1 - page 262, column r, paragraph l * [Y] 1-6,27-30 | |
| SEARCH | - SCHIRRMACHER V ET AL, "Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine", GENE THERAPY, NATURE PUBLISHING GROUP, GB, (20000701), vol. 7, no. 13, doi:10.1038/SJ.GT.3301220, ISSN 0969-7128, pages 1137 - 1147, XP002359468 [X] 1-8 * abstract * * page 1137, column l, paragraph 1 - page 1144, column r, paragraph 2 * [Y] 1-10 [I] 1-10 | |
| SEARCH | - JEFFREY WEBER, "Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer-Preclinical Background: CTLA-4 and PD-1 Blockade", SEMINARS IN ONCOLOGY, W.B. SAUNDERS, US, (20101001), vol. 37, no. 5, doi:10.1053/J.SEMINONCOL.2010.09.005, ISSN 0093-7754, pages 430 - 439, XP009177527 [I] 1-6,27-30 * abstract * * page 430, column l, paragraph 1 - page 435, column r, paragraph 2 * [Y] 1-6,27-30 | |
| SEARCH | - PUTZER BRIGITTE M ET AL, "Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (19970101), vol. 94, no. 20, doi:10.1073/PNAS.94.20.10889, ISSN 0027-8424, pages 10889 - 10894, XP002421569 [I] 1-6,27-30 * abstract * * page 10889, column l, paragraph 1 - page 10894, column l, paragraph 2 * [Y] 1-6,27-30 | |
| SEARCH | - WILGENHOF S ET AL, "A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients", ANNALS OF ONCOLOGY, OXFORD UNIVERSITY PRESS, GB, (20131001), vol. 24, no. 10, ISSN 1569-8041, pages 2686 - 2693, XP009174113 [X] 1-6,27-30 * abstract * * page 2686 - page 2693, column l, paragraph 4 * [Y] 1-6,27-30 [I] 1-6,27-30 | |
| SEARCH | - ELIAS J SAYOUR ET AL, "Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, (20150421), vol. 3, no. 1, doi:10.1186/S40425-015-0058-0, ISSN 2051-1426, page 13, XP021216038 [X] 1-6,9 * abstract * * page 1, column l, paragraph 1 - page 5, column l, paragraph 2 * [Y] 1-10 [I] 1-10 | |
